Fumio Miyamoto

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes

Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami et al. · Journal of Atherosclerosis and Thrombosis · 2017 · 103 citations · Full text

The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus

Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami et al. · Internal Medicine · 2018 · 76 citations · Full text

Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus

Noboru Kurinami, Seigo Sugiyama, Akira Yoshida et al. · Diabetes Research and Clinical Practice · 2018 · 63 citations

Obesity, Metabolic Syndrome, Liver Fat Accumulation +12

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Hideaki Jinnouchi, Seigo Sugiyama, Akira Yoshida et al. · Journal of Diabetes Research · 2015 · 54 citations · Full text

Correlation of body muscle/fat ratio with insulin sensitivity using hyperinsulinemic-euglycemic clamp in treatment-naïve type 2 diabetes mellitus

Noboru Kurinami, Seigo Sugiyama, Akira Yoshida et al. · Diabetes Research and Clinical Practice · 2016 · 32 citations

Obesity, Metabolic Syndrome, Insulin Sensitivity +9